Q1 FY2027 · ended Jun 30, 2026 · Revenue $6.41M, +59.6% YoY · Filed Aug 6, 2026
Sonoma Pharmaceuticals, Inc. (SNOA) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q1 of fiscal 2027, the quarter ended Jun 30, 2026, it reported revenue of $6.4 million and a net loss of $330,000. Free cash flow was -$651,000. As of Jun 30, 2026 it held $5.3 million in cash and investments and $739,000 in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- SNOA (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Boulder, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1367083
- Former names
- Oculus Innovative Sciences, Inc. (until Dec 2, 2016)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
Q1 FY2026 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $6.4M | $5.6M | $4.3M | $5.6M | $4.0M |
| Operating income | -$40,000 | -$351,000 | -$678,000 | -$337,000 | -$1.1M |
| Net income | -$330,000 | -$581,000 | -$819,000 | -$534,000 | -$1.2M |
| Diluted EPS | -$0.09 | -$0.33 | -$0.48 | -$0.32 | -$0.76 |
| Operating cash flow | -$649,000 | -$519,000 | -$764,000 | -$635,000 | -$2.0M |
| Free cash flow | -$651,000 | -$548,000 | -$811,000 | -$645,000 | -$2.1M |
| Total assets | $18.1M | $14.0M | $13.6M | $13.9M | $14.6M |
| Total liabilities | $11.5M | $10.9M | $10.2M | $10.1M | $10.5M |
| Stockholders' equity | $6.6M | $3.1M | $3.4M | $3.8M | $4.1M |
| Cash and investments | $5.3M | $2.4M | $2.6M | $3.0M | $3.6M |
| Total debt | $739,000 | $842,000 | $655,000 | $535,000 | $675,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 17, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 19, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 18, 2026 |
| 10-K | Annual report | Jun 16, 2026 | Mar 31, 2026 |
All 977 Sonoma Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.